🔎 Trials Near Me

Utama › Epidermolisis Bulosa Distrofika › California

Kajian klinikal Epidermolisis Bulosa Distrofika di California

7 kajian untuk Epidermolisis Bulosa Distrofika sedang mencari peserta di lokasi di California.

Bandar di California

Teks kajian rasmi (Bahasa Inggeris)

A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez

  • Lucile Packard Children's Hospital, Palo Alto
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 28 Sep 2026 · NCT06423573

A Long-Term Safety Follow-up Registry for Patients Who Received Treatment With Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) in the Post-Marketing Setting

  • Lucile Packard Children's Hospital, Palo Alto
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 14 Jul 2026 · NCT07700966

Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa

  • Stanford University, Redwood City
Mengambil pesertaFasa 1/2
Umur 6 ke atas · Semua jantina · Dikemas kini 5 Mei 2026 · NCT06834035

Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa

  • Stanford University School of Medicine, Stanford
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 24 Apr 2026 · NCT01019148

A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa

  • Mission Dermatology Center, Rancho Santa Margarita
Mengambil pesertaFasa 3
6 Months · Semua jantina · Dikemas kini 12 Mac 2026 · NCT07016750

MSC EVs in Dystrophic Epidermolysis Bullosa

  • USC /Norris Comprehensive Cancer Center University of Southern California, Los Angeles
Mengambil pesertaFasa 1/2
6 Months · Semua jantina · Dikemas kini 25 Jun 2025 · NCT04173650

Long-Term Follow-up Protocol

  • Mission Dermatology Center, Rancho Santa Margarita
  • Stanford University, Redwood City
Mengambil pesertaKajian pemerhatian
6 Months · Semua jantina · Dikemas kini 8 Jun 2021 · NCT04917887

Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.